|
| 36066725 | Pertuzumab, trastuzumab, and chemotherapy in HER2-positive gastric/gastroesophageal junction cancer: end-of-study analysis of the JACOB phase III randomized clinical trial. | Gastric Cancer | 2023 |
| 37490286 | ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma. | Clin Cancer Res | 2023 |
| 37524953 | Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. | Nat Med | 2023 |
| 37856106 | Chemotherapy and Immune Checkpoint Blockade for Gastric and Gastroesophageal Junction Adenocarcinoma. | JAMA Oncol | 2023 |
| 37731056 | Neoadjuvant botensilimab plus balstilimab response pattern in locally advanced mismatch repair proficient colorectal cancer. | Oncogene | 2023 |
| 37085570 | Improving outcomes in patients with oesophageal cancer. | Nat Rev Clin Oncol | 2023 |
| 37286304 | Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer. | J Immunother Cancer | 2023 |
| 37072891 | Long COVID in Cancer: A Matched Cohort Study of 1-year Mortality and Long COVID Prevalence Among Patients With Cancer Who Survived an Initial Severe SARS-CoV-2 Infection. | Am J Clin Oncol | 2023 |
| 37068504 | Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. | Lancet | 2023 |
| 36611031 | Integrated clinical and genomic analysis identifies driver events and molecular evolution of colitis-associated cancers. | Nat Commun | 2023 |
| 36603169 | Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline. | J Clin Oncol | 2023 |
| 36503738 | Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C Study. | Clin Colorectal Cancer | 2023 |
| 36821805 | Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Q and A. | JCO Oncol Pract | 2023 |
| 34255552 | Redefining Intermediate-Stage HCC Treatment in the Era of Immune Therapies. | JCO Oncol Pract | 2022 |
| 35833783 | Randomized, Double-Blind, Placebo-Controlled Phase III Study of Paclitaxel ± Napabucasin in Pretreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. | Clin Cancer Res | 2022 |
| 35852104 | T cell-inflamed gene expression profile and PD-L1 expression and pembrolizumab efficacy in advanced esophageal cancer. | Future Oncol | 2022 |
| 36970057 | Circulating IgA Antibodies Against <i>Fusobacterium nucleatum</i> Amyloid Adhesin FadA are a Potential Biomarker for Colorectal Neoplasia. | Cancer Res Commun | 2022 |
| 36215283 | Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer. | PLoS One | 2022 |
| 36267012 | Nivolumab plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastroesophageal junction cancer-regional differences in efficacy. | Ann Palliat Med | 2022 |
| 35947675 | Adenoviral-based vaccine promotes neoantigen-specific CD8<sup>+</sup> T cell stemness and tumor rejection. | Sci Transl Med | 2022 |
| 35267477 | Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies. | Cancers (Basel) | 2022 |
| 33253786 | Development of the Oncolo-GIST ("Giving Information Strategically & Transparently") Intervention Manual for Oncologist Skills Training in Advanced Cancer Prognostic Information Communication. | J Pain Symptom Manage | 2021 |
| 33826550 | Impact of Use of Antibiotics on Response to Immune Checkpoint Inhibitors and Tumor Microenvironment. | Am J Clin Oncol | 2021 |
| 33533655 | KEYNOTE-975 study design: a Phase III study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma. | Future Oncol | 2021 |
| 33497249 | Reply to K. de Joode et al. | J Clin Oncol | 2021 |
| 33577358 | Phase III Study to Evaluate Efficacy and Safety of Andecaliximab With mFOLFOX6 as First-Line Treatment in Patients With Advanced Gastric or GEJ Adenocarcinoma (GAMMA-1). | J Clin Oncol | 2021 |
| 34941969 | Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer. | PLoS One | 2021 |
| 34893523 | Randomized, open-label, phase 2 study of andecaliximab plus nivolumab versus nivolumab alone in advanced gastric cancer identifies biomarkers associated with survival. | J Immunother Cancer | 2021 |
| 34672971 | CLIP-170S is a microtubule +TIP variant that confers resistance to taxanes by impairing drug-target engagement. | Dev Cell | 2021 |
| 34408323 | Dietary fructose improves intestinal cell survival and nutrient absorption. | Nature | 2021 |
| 34407392 | Dysregulation of ILC3s unleashes progression and immunotherapy resistance in colon cancer. | Cell | 2021 |
| 34406872 | Immunotherapy in Patients With Locally Advanced Esophageal Carcinoma: ASCO Treatment of Locally Advanced Esophageal Carcinoma Guideline Rapid Recommendation Update. | J Clin Oncol | 2021 |
| 34548190 | Implications of reactive oxygen species on cancer formation and its treatment. | Semin Oncol | 2021 |
| 34454674 | Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. | Lancet | 2021 |
| 34160456 | Favorable response to second-line atezolizumab and bevacizumab following progression on nivolumab in advanced hepatocellular carcinoma: A case report demonstrating that anti-VEGF therapy overcomes resistance to checkpoint inhibition. | Medicine (Baltimore) | 2021 |
| 34288262 | Toward a Treatment Sequencing Strategy: A Systematic Review of Treatment Regimens in Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma. | Oncologist | 2021 |
| 34286887 | Validation of a Circulating Tumor DNA-Based Next-Generation Sequencing Assay in a Cohort of Patients with Solid tumors: A Proposed Solution for Decentralized Plasma Testing. | Oncologist | 2021 |
| 34168263 | Androgen receptor variant shows heterogeneous expression in prostate cancer according to differentiation stage. | Commun Biol | 2021 |
| 31580753 | Palliative Chemotherapy or Radiation and Prognostic Understanding among Advanced Cancer Patients: The Role of Perceived Treatment Intent. | J Palliat Med | 2020 |
| 33026938 | Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer. | J Clin Oncol | 2020 |
| 33046621 | Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors. | J Immunother Cancer | 2020 |
| 33148789 | Comparative effectiveness of treatment modalities in non-metastatic gastric adenocarcinoma: a propensity score matching analysis of the National Cancer Database. | BMJ Open Gastroenterol | 2020 |
| 32662880 | Hematology and oncology clinical care during the coronavirus disease 2019 pandemic. | CA Cancer J Clin | 2020 |
| 32990737 | Clinical Screening for COVID-19 in Asymptomatic Patients With Cancer. | JAMA Netw Open | 2020 |
| 32986528 | COVID-19 Severity and Outcomes in Patients With Cancer: A Matched Cohort Study. | J Clin Oncol | 2020 |
| 32755482 | Metastatic Pancreatic Cancer: ASCO Guideline Update. | J Clin Oncol | 2020 |
| 32812320 | Safety and Efficacy of Andecaliximab (GS-5745) Plus Gemcitabine and Nab-Paclitaxel in Patients with Advanced Pancreatic Adenocarcinoma: Results from a Phase I Study. | Oncologist | 2020 |
| 32641434 | Multicenter Phase II Study of Cabazitaxel in Advanced Gastroesophageal Cancer: Association of HER2 Expression and M2-Like Tumor-Associated Macrophages with Patient Outcome. | Clin Cancer Res | 2020 |
| 32172199 | Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative. | Eur J Cancer | 2020 |
| 32321717 | Microtubule Engagement with Taxane Is Altered in Taxane-Resistant Gastric Cancer. | Clin Cancer Res | 2020 |